Virkel G, Lifschitz A, Sallovitz J, Pis A, Lanusse C
Laboratorio de Farmacologia, Departmento de Fisiopatologia, Nuncleo Fisfarvet, Facultad de Ciencias Veterinarias, UNCPBA, Tandil, Argentina.
J Vet Pharmacol Ther. 2006 Jun;29(3):213-23. doi: 10.1111/j.1365-2885.2006.00735.x.
Triclabendazole (TCBZ) is an halogenated benzimidazole (BZD) compound worldwide used to control immature and adult stages of the liver fluke Fasciola hepatica. The purpose of this investigation was to characterize in vitro the patterns of hepatic and ruminal biotransformation of TCBZ and its metabolites in sheep. TCBZ parent drug was metabolized into its sulphoxide (TCBZSO), sulphone (TCBZSO2) and hydroxy derivatives by sheep liver microsomes. The same microsomal fraction was also able to oxidize TCBZSO into TCBZSO2 and hydroxy-TCBZSO (HO-TCBZSO). TCBZ sulphoxidation was significantly (P < 0.001) inhibited after inactivation of the flavin-monooxygenase (FMO) system (77% inhibition) as well as in the presence of the FMO substrate methimazole (MTZ) (71% inhibition). TCBZ sulphoxidative metabolism was also reduced (24% inhibition, P < 0.05) by the cytochrome P450 inhibitor piperonyl butoxide (PB). The rate of TCBZSO conversion into TCBZSO2 was also significantly inhibited by PB (55% inhibition), MTZ (52% inhibition) and also following FMO inactivation (58% inhibition). The data reported here indicate that the FMO is the main enzymatic pathway involved in TCBZ sulphoxidation (ratio FMO/P450 = 3.83 +/- 1.63), although both enzymatic systems participate in a similar proportion in the sulphonation of TCBZSO to form the sulphone metabolite (ratio FMO/P450 = 1.31 +/- 0.23). Additionally, ketoconazole (KTZ) did not affect TCBZ sulphoxidation but decreased (66% inhibition, P < 0.05) the formation of TCBZSO2. Similarly, inhibition of TCBZSO2 production was observed after incubation of TCBZSO in the presence of KTZ and erythromycin (ETM). Conversely, thiabendazole (TBZ) and fenbendazole (FBZ) did not affect the oxidative metabolism of both incubated substrates. The sheep ruminal microflora was able to reduce the sulphoxide (TCBZSO) into the parent thioether (TCBZ). The ruminal sulphoreduction of the HO-TCBZSO derivative into HO-TCBZ was also demonstrated. The rate of sulphoreduction of HO-TCBZSO was significantly (P < 0.05) higher than that observed for TCBZSO. The metabolic approach tested here contributes to the identification of the different pathways involved in drug biotransformation in ruminant species. These findings on the pattern of hepatic and ruminal biotransformation of TCBZ and its main metabolites are a further contribution to the understanding of the pharmacological properties of widely used anthelmintics in ruminants. Comprehension of TCBZ metabolism is critical to optimize its flukicidal activity.
三氯苯达唑(TCBZ)是一种卤代苯并咪唑(BZD)化合物,在全球范围内用于控制肝片吸虫(Fasciola hepatica)的未成熟和成虫阶段。本研究的目的是在体外表征绵羊体内TCBZ及其代谢产物的肝脏和瘤胃生物转化模式。绵羊肝脏微粒体将TCBZ原药代谢为其亚砜(TCBZSO)、砜(TCBZSO2)和羟基衍生物。同一微粒体部分也能够将TCBZSO氧化为TCBZSO2和羟基 - TCBZSO(HO - TCBZSO)。黄素单加氧酶(FMO)系统失活后(77%抑制)以及在FMO底物甲巯咪唑(MTZ)存在下(71%抑制),TCBZ的亚砜化显著(P < 0.001)受到抑制。细胞色素P450抑制剂胡椒基丁醚(PB)也降低了TCBZ的亚砜化代谢(24%抑制,P < 0.05)。PB(55%抑制)、MTZ(52%抑制)以及FMO失活后(58%抑制),TCBZSO转化为TCBZSO2的速率也显著受到抑制。此处报告的数据表明,FMO是参与TCBZ亚砜化的主要酶促途径(FMO/P450比率 = 3.83 ± 1.63),尽管两种酶促系统在将TCBZSO磺化为砜代谢产物的过程中参与比例相似(FMO/P450比率 = 1.31 ± 0.23)。此外,酮康唑(KTZ)不影响TCBZ的亚砜化,但降低了(66%抑制,P < 0.05)TCBZSO2的形成。同样,在KTZ和红霉素(ETM)存在下孵育TCBZSO后,观察到TCBZSO2生成受到抑制。相反,噻苯达唑(TBZ)和芬苯达唑(FBZ)不影响两种孵育底物的氧化代谢。绵羊瘤胃微生物群能够将亚砜(TCBZSO)还原为母体硫醚(TCBZ)。还证实了HO - TCBZSO衍生物在瘤胃中的硫还原为HO - TCBZ。HO - TCBZSO的硫还原速率显著(P < 0.05)高于TCBZSO。此处测试的代谢方法有助于确定反刍动物物种中药物生物转化所涉及的不同途径。这些关于TCBZ及其主要代谢产物的肝脏和瘤胃生物转化模式的发现,进一步有助于理解反刍动物中广泛使用的驱虫药的药理特性。了解TCBZ的代谢对于优化其杀吸虫活性至关重要。